title: [Multiple eruptive keratoacanthoma disclosing lymphoma].
authors.affiliation: Service de Dermatologie, Hôpital Saint-Louis, Paris.
authors.forename: P P
authors.initials: PP
authors.lastname: Cabotin
authors.forename: M D
authors.initials: MD
authors.lastname: Vignon-Pennamen
authors.forename: J M
authors.initials: JM
authors.lastname: Miclea
authors.forename: M F
authors.initials: MF
authors.lastname: D'Agay
authors.forename: D
authors.initials: D
authors.lastname: Wallach
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005050:Etretinate / Q000627:therapeutic use; D005148:Facial Dermatoses / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007636:Keratoacanthoma / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D008223:Lymphoma / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D009059:Mouth Diseases / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D009061:Mouth Mucosa / Q000473:pathology; D011239:Prednisolone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005050:Etretinate; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone
vernacular_title: Kérato-acanthomes multiples éruptifs révélateurs d'un lymphome.